Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

minocycline hydrochloride

MINOCYCLINE HYDROCHLORIDE

minocycline hydrochloride (MINOCYCLINE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 14
Pipeline programs 7
News articles 0
Drug details — minocycline hydrochloride
US status
approved
Class
—
Route
TOPICAL
Patents
14
Programs
7
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

minocycline hydrochloride (MINOCYCLINE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN minocycline hydrochloride
Brand MINOCYCLINE HYDROCHLORIDE
Mechanism Bacterial 70S ribosome inhibitor
Target Bacterial 70S ribosome
Route TOPICAL
Formulation TABLET, EXTENDED RELEASE
Originator Teva Pharma GmbH

Mechanism of action

Bacterial 70S ribosome inhibitor

Primary target: Bacterial 70S ribosome

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. 61186372NSC2007 Phase 2 · Janssen-Cilag International N.V · EGFR-mutated Advanced or Metastatic Non-small Cell Lung Canc
  2. MINOCIN 100 mg capsule rigide Phase 2 · Farmatek · Depression
  3. Minocycline Hydrochloride Phase 2 · United Therapeutics Europe · Acute Pain
  4. Minocycline Phase 1 · United Therapeutics Europe · Alcohol Dependence
  5. Minocycline Approved · First People's Hospital · Ischemic Stroke, Acute
  6. Minocycline Approved · BRIGHT MINDS BIOSCIENCES · Schizophrenia
  7. Minocycline Unknown · First People's Hospital · Intracerebral Hemorrhage

Related & competitor drugs

Browse all drugs
  1. azithromycin Bacterial 70S ribosome inhibitor
  2. chloramphenicol Bacterial 70S ribosome inhibitor
  3. clarithromycin Bacterial 70S ribosome inhibitor
  4. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  5. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin phosphate Bacterial 70S ribosome inhibitor

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11135244

    Stem cell culture media and methods of enhancing cell survival

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11052118

    Enhanced stem cell composition

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10980838

    Methods of treating ischemia

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10946101

    Surfactant-free water-free foamable compositions, breakable foams and gels and their uses

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10851412

    Cell potency assay for therapeutic potential

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10172888

    Enhanced stem cell composition

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10111907

    Methods of treating ischemia

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9943545

    Stem cell culture media and methods of enhancing cell survival

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9873722

    Wnt compositions and therapeutic uses of such compositions

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9452186

    Enhanced stem cell composition

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9403885

    Wnt compositions and therapeutic uses of such compositions

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9370510

    Small molecule compounds to treat hearing loss

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 6103269

    Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies

    Expires Mon Aug 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is minocycline hydrochloride?

minocycline hydrochloride (MINOCYCLINE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for minocycline hydrochloride?

MINOCYCLINE HYDROCHLORIDE is a marketed brand name for minocycline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of minocycline hydrochloride?

minocycline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.